The role of interval debulking surgery in ovarian cancer

Current Oncology Reports

Volumn 5, Issue 6, 2003, Pages 473-481

  van der Burg, Maria E L ^a   Vergote, Ignace ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MEDICAL SPECIALIST; MINIMAL RESIDUAL DISEASE; MORBIDITY; MORTALITY; OVARY CANCER; PROGNOSIS; REVIEW; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; GYNECOLOGIC SURGERY; METHODOLOGY; OVARY TUMOR; WOMEN'S HEALTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; WOMEN'S HEALTH;

EID: 1942462676     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0008-8     Document Type: Review

References (47)

1. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975, 42:1010-1014.
2. Griffiths CT, Park LM, Fuller AF: Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 1979, 63:235-240.
3. Neijt JP, Ten Bokkel Huinink WW, Van der Burg MEL, et al.: Long-term survival in ovarian cancer: mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991, 27:1367-1372.
4. Omura GA, Bundy BN, Berek JS et al.: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 1989, 7:457-465.
5. Weber AM, Kennedy AW: The role of bowel resection in the primary surgical debulking of carcinoma of the ovary. J Am Coll Surg 1994, 179:465-470.
6. Bertelsen K: Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 1990, 38:203-209.
7. Bristow RE, Tomacruz RS, Armstrong DK, et al.: Survival effect of maximal cytoreductive surgery for ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259.
8. Griffiths CT, Parker LM, Lee S, Finkler NJ: The effect of residual mass size on response to chemotherapy after surgical cytoreduction for advanced ovarian cancer: long-term results. Int J Gynecol Cancer 2002, 12:323-331.
9. McGuire WP, Hoskins WJ, Brady MF, et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with advanced stage III and stage IV ovarian cancer. N Engl J Med 1996, 34:3-6.
10. Piccart MJ, Bertelsen K, James K, et al.: Randomized Intergroup trial of cisplatin-paclitaxel vs. cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. J Natl Cancer Inst 2000, 92:699-709.
11. Skipper H: Thoughts on cancer chemotherapy and combination modality therapy. JAMA 1974, 230:1033-1035.
12. DeVita VT: The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 1983, 51:1209-1220.
13. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727-1734.
14. Michel G, De Laco P, Castaigne D, et al.: Extensive cytoreductive surgery in advanced ovarian cancer. Eur J Gynecol Oncol 1997, 18:9-15.
15. Curtins JP, Malik R, Venkatraman ES, et al.: Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997, 64:9-12.
16. Liu PC, Benjamin I, Morgan MA, et al.: Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997, 64:4-8.
17. Munkarah AR, Hallum AV, Morris M et al.: Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997, 64:13-17.
18. Bristow RE, Montz FJ, Lagasse LD, et al.: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999, 72:278-287.
19. Naik R, Nordin A, Cross PA, et al.: Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol 2000, 78:2:171-175.
20. Hoskins WJ, Bundy BN, Thipgen T, et al.: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1992, 47:159-166.
21. Eisenkop S, Nalick R, Wang HJ, et al.: Peritoneal implant excision or ablation during cytoreductive surgery: the impact on survival [abstract]. Gynecol Oncol 1992, 51:224-229.
22. Farias-Eisner R, Teng F, Oliveira M, et al.: Influence of tumor grade, distribution and extent of carcinomatosis in minimal residual disease stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 1994, 55:108-110.
23. Vergote I, De Wever IW, Tjalma W, et al.: Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 1998, 71:413-416.
24. Vergote I, De Wever IW, Decloedt J, et al.: Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 2000, 27:31-36.
25. Scarabelli C, Gallo A, Franceschi S, et al.: Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 2000, 88:389-397.
26. Petignat P, Vajda D, Joris F, Obrist R: Surgical management of epithelial ovarian cancer at community hospitals: a population-based study. J Surg Oncol 2000, 75:19-23.
27. Lichtenegger W, Sehouli J, Buchmann E, et al.: Operative results of primary and secondary debulking-operations in advanced ovarian cancer. J Obstet Gynaecol Res 1998, 24:447-451.
28. Chen L, Leuchter RS, Lagasse LD, Karlan BY: Splenectomy and surgical cytoreduction for ovarian cancer. Gynecol Oncol 2000, 77:362-368.
29. Robinson JB, In DD, Rosenshein NB, McGuire WP: Aggressive or conservative surgery for ovarian cancer? In Clinical Management of Ovarian Cancer. Edited by Ledermann JA, Hoskins WJ, Kaye SB. Oxford, UK: Blackwell Science; 2001:21-45.
30. Neijt JP, Ten Bokkel Huinink WW, Van der Burg MEL, et al.: Randomized trial comparing combination chemotherapy regimens (HEXA-CAF vs. CHAP5) in advanced ovarian carcinoma. Lancet 1984, 2:594-600.
31. Wils J, Blijham A, Naus A, et al.: Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 1986, 4:1068-1073.
32. Jacob JH, Gershenson DM, Morris M, et al.: Neoadjuvant chemotherapy and interval debulking surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1991, 42:146-150.
33. Neijt JP, Ten Bokkel Huinink WW, Van der Burg MEL, et al.: Randomized trial comparing two combination chemotherapy regimens (CHAP5 vs. CP) in advanced ovarian carcinoma. J Clin Oncol 1987, 5:1157-1168.
34. Lawton FG, Redman CWE, Luesley DM, et al.: Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced unresected epithelial ovarian cancer. Obstet Gynecol 1989, 73:61-65.
35. Van der Burg MEL, Van Lent M, Buyse M, et al.: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995, 332:629-634.
36. Rose PG, Nerenstone S, Brady M, et al.: A phase III randomized study of interval secondary cytoreduction in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study [abstract]. Proc ASCO 2002, 21:201a.
37. Van der Burg MEL, van Lent M, Kobierska A, et al.: Interval debulking surgery significantly increases the survival and progression free survival in advanced epithelial ovarian cancer patients: an EORTC Gynaecological Cancer Co-operative Group study. In Ovarian Cancer. Edited by Jacobs IJ, Shepherd JH, Oram DH, et al. Oxford, UK: Oxford University Press; 2002:299-303.
38. Venesmaa P, Ylikorkala O: Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 1992, 79:168-172.
39. Ng LW, Rubin SC, Hoskins WJ, et al.: Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 1990, 38:358-363.
40. Van der Burg MEL: Advanced ovarian cancer. Curr Treat Opt Oncol 2001, 1:109-118.
41. Hacker NF, Berek JS, Lagasse LD, et al.: Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983, 61:413-420.
42. Schwartz PE, Rutherford TJ, Chambers JT, et al.: Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 1999, 71:93-99.
43. Kayikçioǧlu F, Köse MF, Boran N, et al.: Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001, 11:466-470.
44. Ansquer Y, Leblanc E, Clough K, et al.: Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 2001, 91:2329-2334.
45. Chan YM, Ng TY, Ngan HYS, Wong LC: Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 2003, 88:9-16.
46. Kuhn W, Rutke S, Späthe K, et al.: Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics stage IIIc ovarian carcinoma. Cancer 2001, 92:2585-2591.
47. Hueber J, Meyer A, Wagner U, Wallwiener D: The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol 2002, 128:153-160.